全文获取类型
收费全文 | 12144篇 |
免费 | 1674篇 |
国内免费 | 204篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 312篇 |
妇产科学 | 103篇 |
基础医学 | 998篇 |
口腔科学 | 103篇 |
临床医学 | 827篇 |
内科学 | 1192篇 |
皮肤病学 | 206篇 |
神经病学 | 663篇 |
特种医学 | 1810篇 |
外国民族医学 | 9篇 |
外科学 | 679篇 |
综合类 | 1296篇 |
现状与发展 | 2篇 |
预防医学 | 1321篇 |
眼科学 | 51篇 |
药学 | 2403篇 |
16篇 | |
中国医学 | 295篇 |
肿瘤学 | 1707篇 |
出版年
2024年 | 20篇 |
2023年 | 214篇 |
2022年 | 291篇 |
2021年 | 500篇 |
2020年 | 525篇 |
2019年 | 483篇 |
2018年 | 560篇 |
2017年 | 532篇 |
2016年 | 514篇 |
2015年 | 471篇 |
2014年 | 957篇 |
2013年 | 1094篇 |
2012年 | 791篇 |
2011年 | 822篇 |
2010年 | 622篇 |
2009年 | 551篇 |
2008年 | 545篇 |
2007年 | 506篇 |
2006年 | 408篇 |
2005年 | 340篇 |
2004年 | 312篇 |
2003年 | 270篇 |
2002年 | 259篇 |
2001年 | 223篇 |
2000年 | 181篇 |
1999年 | 174篇 |
1998年 | 149篇 |
1997年 | 147篇 |
1996年 | 120篇 |
1995年 | 119篇 |
1994年 | 112篇 |
1993年 | 108篇 |
1992年 | 87篇 |
1991年 | 91篇 |
1990年 | 85篇 |
1989年 | 98篇 |
1988年 | 72篇 |
1987年 | 66篇 |
1986年 | 66篇 |
1985年 | 100篇 |
1984年 | 88篇 |
1983年 | 51篇 |
1982年 | 66篇 |
1981年 | 57篇 |
1980年 | 54篇 |
1979年 | 44篇 |
1978年 | 13篇 |
1977年 | 25篇 |
1976年 | 14篇 |
1975年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
目的观察健脾温肾软坚解毒方、康艾注射液联合低剂量化疗对老年脾肾两虚型晚期非小细胞肺癌患者瘤灶、免疫功能及无进展生存期的影响。方法将80例老年脾肾两虚型晚期非小细胞肺癌患者随机分为治疗组和对照组,每组40例。对照组予常规剂量化疗,治疗组予健脾温肾软坚解毒方、康艾注射液联合低剂量化疗。化疗2个周期后,观察两组患者瘤灶、免疫功能的变化情况,随访患者的无进展生存期。结果①试验期间,对照组脱落2例,试验组无脱落,最终完成试验者78例,其中治疗组40例,对照组38例。②两组实体瘤疗效比较,差异无统计学意义(P0.05)。③化疗1个周期与化疗前组内比较,两组血清NK、CD3~+、CD4~+、CD8~+水平差异无统计学意义(P0.05);化疗2个周期与化疗前组内比较,治疗组血清CD8~+水平升高(P0.05),对照组血清NK、CD3~+、CD4~+水平降低(P0.05)。化疗1个周期后组间比较,治疗组血清CD3~+、CD4~+水平高于对照组(P0.05);化疗2个周期后组间比较,治疗组血清NK、CD3~+、CD4~+水平高于对照组(P0.05)。④两组患者中位无进展生存时间均为4.5个月,差异无统计学意义(P0.05)。结论健脾温肾软坚解毒方、康艾注射液联合低剂量化疗能有效控制老年肺肾两虚型晚期非小细胞肺癌患者的瘤灶变化,并有利于稳定血清NK、CD3~+和CD4~+水平,保护患者的免疫功能。 相似文献
23.
同步放化疗是不可手术局部晚期食管癌的标准治疗模式,国际推荐根治性放疗剂量为50.0~50.4Gy,但中国食管癌与西方国家在病理类型、生物学行为等方面大有不同,行根治性放疗剂量仍倾向于60Gy。增加放疗剂量能否带来生存获益成为临床亟待解决的问题。有研究认为高剂量放疗可提高局控率、改善生存,但也有研究认为提高剂量未能带来生存获益,且可增加不良反应事件发生率。因此,本文就食管癌根治性放疗剂量对预后的影响进行探讨,并通过放化疗后疗效评估对放疗剂量做出适当调整,以期达个体化放疗。 相似文献
24.
肺癌多是邪祟之物郁结留滞致使人体气血运行不畅所致,周晋华主任认为肺癌的发生与正虚邪害密不可分,而晚期肿瘤患者虚多实少,全身为虚,当以脾虚为主,“得脾胃者得中央,得中央者得天下”,局部为实,故当以缓治,固脾胃之本培人体之元,周晋华主任运用低剂量规律口服环磷酰胺联合中药紫杉片解毒散结配伍,佐以益气健脾之法治疗晚期肺癌患者,发现对身体基础状况较差的老年肿瘤患者有良好的效果,此法是从姑息性治疗角度运用中西医结合的方法将静脉化疗药环磷酰胺改为口服,在提高老年患者对化疗药物的耐受性,减轻化疗副作用方面有一定的优势,为临床治疗晚期肺癌提供一种新思维。 相似文献
25.
26.
27.
分瓶法测定果蝇吸入麻醉药半数麻醉有效浓度 总被引:2,自引:1,他引:1
目的 建立测定果蝇吸入麻醉药半数麻醉有效浓度 (ED50 )的方法学。方法 在 11个 32 5ml的三角烧瓶中各放入 30只雄性果蝇 ,分别加入不同容量的异氟醚标准气 ,使 11个烧瓶中异氟醚浓度分布在零效应浓度与百分之百效应浓度之间。以果蝇失去附壁及运动能力为标准计算各瓶中被麻醉果蝇数 ,用正规法计算出ED50 。结果 11次实验在 2 5及 5 0min时的量 -效关系曲线均呈S形 ,用各自的对数浓度与概率单位作图都呈直线相关 ,相关系数分别为 0 .972± 0 .0 14和 0 .971± 0 .0 2 5 ,ED50 值分别为 (0 .5 1± 0 .0 6 8) %和 (0 .4 7± 0 .0 85 ) % ,变异系数分别为 13.3%和 18.0 %。结论 本法稳定性较好 ,实用可行 相似文献
28.
Despite the widespread use of botulinum toxin to treat muscle dystonias, no method exists to quantify muscle paralysis in either human or nonhuman models. In this study we examined how the location, dose, and volume of botulinum injection affects paralysis in the rat tibialis anterior muscle. Paralysis was quantified by electrically stimulating the nerve to the tibialis anterior and then staining sections of the muscle for glycogen. The areas of glycogen-containing fibers represented regions of botulinum action. The results showed that the most important injection technique is to inject botulinum directly into the motor endplate region of a muscle. Injections only 0.5 cm from the motor endplate resulted in a 50% decrease in paralysis. Increases in dose increased paralysis, however, some of that increase was simply due to the increased volume of injection. Thus, delivering toxin in small volumes near the MEP band of a muscle should produce the most effectiveparalysis. © 1993 John Wiley & Sons, Inc. 相似文献
29.
M. Wensing A. H. Penninks† S. L. Hefle‡ J. H. Akkerdaas§ R. van Ree§ S. J. Koppelman† C. A. F. M. Bruijnzeel-Koomen A. C. Knulst 《Clinical and experimental allergy》2002,32(12):1757-1762
BACKGROUND: The risk for allergic reactions depends on the sensitivity of individuals and the quantities of offending food ingested. The sensitivity varies among allergic individuals, as does the threshold dose of a food allergen capable of inducing an allergic reaction. OBJECTIVE: This study aimed at determining the distribution of minimum provoking doses of hazelnut in a hazelnut-allergic population. METHODS: Thirty-one patients with a history of hazelnut-related allergic symptoms, a positive skin prick test to hazelnut and/or an elevated specific IgE level, were included. Double-blind, placebo-controlled food challenges (DBPCFC) were performed with seven increasing doses of dried hazelnut (1 mg to 1 g hazelnut protein) randomly interspersed with seven placebo doses. RESULTS: Twenty-nine patients had a positive challenge. Itching of the oral cavity and/or lips was the first symptom in all cases. Additional gastrointestinal symptoms were reported in five patients and difficulty in swallowing in one patient. Lip swelling was observed in two patients, followed by generalized urticaria in one of these. Threshold doses for eliciting subjective reactions varied from a dose of 1 mg up to 100 mg hazelnut protein (equivalent to 6.4-640 mg hazelnut meal). Extrapolation of the dose-response curve showed that 50% of our hazelnut-allergic population will suffer from an allergic reaction after ingestion of 6 mg (95% CI, 2-11 mg) of hazelnut protein. Objective symptoms were observed in two patients after 1 and 1,000 mg, respectively. CONCLUSION: DBPCFCs demonstrated threshold doses in half of the hazelnut-allergic patients similar to doses previously described to be hidden in consumer products. This stresses the need for careful labelling and strategies to prevent and detect contamination of food products with hazelnut residues. 相似文献
30.
Prediction of steady state bioequivalence relationships using single dose data II-nonlinear kinetics
A J Jackson 《Biopharmaceutics & drug disposition》1989,10(5):489-503
Two nonlinear pharmacokinetic models were simulated to investigate the relationship between single and multiple dose bioequivalency parameters for drugs such as phenytoin and propranolol which exhibit either saturable elimination kinetics or a capacity limited first pass effect. Mean Tmax, Cmax and area under the plasma-concentration time curve values from 0 to infinity (AUC 0-infinity) were compared after a single and multiple dose(s) of a test or reference drug. The aim was to determine if there were systematic changes in the limits of the single dose confidence interval at steady state that would limit the usefulness of confidence intervals following a single dose in accurately predicting bioavailability following multiple dosing. The 90 per cent confidence interval expressed as a percentage of the reference mean for Tmax, Cmax, and AUC 0-infinity showed model dependent changes from single to multiple dosing in response to the level of data error and changes in absorption. Changes in clearance also seemed to have a marked effect on the observed limits of the single and multiple dose confidence intervals especially for Cmax which showed a characteristic change in the intervals as a function of the clearance ratio. The model used to describe phenytoin had confidence intervals for Cmax and AUC 0-infinity from single to multiple dosing that were similar to that seen for the experimental data. However, the model predictions for Tmax confidence intervals following single and multiple dosing was at variance with the experimental data for formulations A and B. 相似文献